Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-nmvwc Total loading time: 0 Render date: 2024-07-06T20:59:18.908Z Has data issue: false hasContentIssue false

16 - Breast

Published online by Cambridge University Press:  23 December 2009

By
Nayyer Iqbal  and
Peter Barrett-Lee
Edited by
Louise Hanna ,
Tom Crosby  and
Fergus Macbeth
Nayyer Iqbal
Affiliation:
Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
Peter Barrett-Lee
Affiliation:
Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Hospital, Cardiff
Get access

Summary

Introduction

The lifetime risk of breast cancer in women is one in nine. Breast cancer most commonly presents as a lump in the breast, but the use of screening has also allowed very early cancers to be diagnosed before they can be detected clinically. The management of breast cancer has changed dramatically. In the past, patients were treated with radical mastectomy, whereas today, patients are usually treated with breast-conserving techniques – wide local excision and radiotherapy. The past few decades have also seen the wider use and development of systemic therapies: hormonal treatments, chemotherapy and, recently, the monoclonal antibody trastuzumab. As a result, there has been a steady fall in the mortality from breast cancer.

Types of tumour affecting the breast

Table 16.1 shows the range of tumours that can affect the breast.

Anatomy

The female breast extends from the 2nd to the 6th rib, and it is made up of 15 to 20 lobes which radiate out from the nipple. The nipple is surrounded by the areola. Each breast is divided into a central portion and four quadrants. The upper outer quadrant also contains the axillary tail. The lymphatic drainage from the breast is primarily to the axillary lymph nodes but also to the internal mammary nodes, which lie in the thorax alongside the internal thoracic artery. A few lymphatic channels also communicate with those in the opposite breast and in the abdominal wall.

Type
Chapter
Information
Practical Clinical Oncology , pp. 190 - 213
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ahn, P. H., Vu, H. T., Lannin, D.et al. (2005). Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J. Clin. Oncol., 23, 17–23.CrossRefGoogle Scholar
Albain, K., Barlow, W., O'Malley, F.et al. (2004a). Concurrent (CAFT) versus sequential (cyclophosphamide, doxorubicin, 5-FU-T) chemo hormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (oestrogen receptor) and/or progesterone (progesterone receptor) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (Southwest Oncology Group-8814). Breast Cancer Res. Treat., 88 (Suppl. 1), A-37.Google Scholar
Albain, K. S., Nag, S., Calderillo-Ruiz, G.et al. (2004b). Global phase III study of gemcitabine plus paclitaxel (gemcitabine, paclitaxel) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (metastatic breast cancer): first report of overall survival. Proc. Am. Soc. Clin. Oncol., 23 (5), Abstr. 510.Google Scholar
,Anonymous. (1996). Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet, 347, 1713–27.CrossRefGoogle Scholar
Arriagada, R., Le, M. C., Mouriesse, H.et al. (1988). Long-term effect of internal mammary chain treatment. Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes. Radiother. Oncol., 11, 213–22.CrossRefGoogle ScholarPubMed
Bartelink, H., Horiot, J.-C., Poortmans, P.et al. (2001). Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N. Engl. J. Med., 345, 1378–87.CrossRefGoogle ScholarPubMed
Beral, V. and Million Women Study Collaborators. (2003). Breast cancer and hormone replacement therapy in the Million Women Study. Lancet, 362, 419–27.CrossRefGoogle ScholarPubMed
Bhatnagar, A. S. (2006). Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting. Breast, 15 (Suppl. 1), S3–13.CrossRefGoogle ScholarPubMed
Bijker, N., Meijnen, P. H., Bogaerts, J.et al. (2005). Radiotherapy in breast-conserving treatment for ductal carcinoma in situ (ductal carcinoma in situ): ten-year results of European Organisation for Research and Treatment of Cancer (European Organisation for Research and Treatment of Cancer) randomized trial 10853. San Antonio Breast Cancer Symposium 2005, San Anton, Abstr. 7.Google Scholar
Blamey, R. W. (1996). The design and clinical use of the Nottingham Prognostic Index in breast cancer. Breast, 5, 156–7.CrossRefGoogle Scholar
Bonadonna, G., Valagussa, P., Moliterni, A.et al. (1995). Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node positive breast cancer; the results of 20 years of follow-up. N. Engl. J. Med., 332, 901–6.CrossRefGoogle ScholarPubMed
Bonadonna, G., Moliterni, A., Zambetti, M.et al. (2005). 30 years' follow-up of randomised studies of adjuvant cyclophosphamide, methotrexate, 5-FU in operable breast cancer: cohort study. B. M. J., 330, 217.CrossRefGoogle ScholarPubMed
Brown, J. E. and Coleman, R. E. (2002). The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res., 4, 24–9.CrossRefGoogle ScholarPubMed
Budman, D. R., Berry, D., Cirrincione, C. T.et al. (1998). Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J. Natl. Cancer Inst., 90, 1205–11.CrossRefGoogle ScholarPubMed
Buzdar, A. U., Singletary, S. E., Valero, V.et al. (2002). Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin. Cancer Res., 8, 1073–9.Google ScholarPubMed
Citron, M. L., Berry, D. A., Cirrincione, C.et al. (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol., 21, 1431–9.CrossRefGoogle Scholar
Cobleigh, M. A., Vogel, C. L., Tripathy, D.et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17, 2639–48.CrossRefGoogle Scholar
Cody, H. S. III. (1999). Sentinel lymph-node mapping in breast cancer. Oncology (Williston Park), 13, 25–34.Google ScholarPubMed
Coleman, M. P., Gatta, G., Verdecchia, A.et al. (2003). EUROCARE-3 summary: cancer survival in Europe at the end of the 20th Century. Ann. Oncol., 14 (Suppl. 5), v128–49.CrossRefGoogle ScholarPubMed
Colleoni, M., Viale, G., Zahrieh, D.et al. (2004). Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res., 10, 6622–8.CrossRefGoogle Scholar
Coombes, R. C., Hall, E., Gibson, L. J.et al. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med., 350, 1081–92.CrossRefGoogle ScholarPubMed
Dellapasqua, S., Colleoni, M., Gelber, R. D.et al. (2005). Adjuvant endocrine therapy for premenopausal women with early breast cancer. J. Clin. Oncol., 23, 1736–50.CrossRefGoogle ScholarPubMed
Early Breast Cancer Trialists' Collaborative Group. (1995). Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N. Engl. J. Med., 333, 1444–55.CrossRef
Early Breast Cancer Trialists' Collaborative Group. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687–717.CrossRef
Eedarapalli, P. and Jain, S. (2006). Breast cancer in pregnancy. J. Obstet. Gynaecol., 26, 1–4.CrossRefGoogle ScholarPubMed
Fisher, B., Montague, E., Redmond, C.et al. (1980). Findings from National Surgical Adjuvant Breast and Bowel Project Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome. Cancer, 46, 1–13.3.0.CO;2-3>CrossRefGoogle Scholar
Fisher, B., Brown, A. M., Dimitrov, N. V.et al. (1990). Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J. Clin. Oncol., 8, 1483–96.CrossRefGoogle ScholarPubMed
Fisher, B., Dignam, J., Wolmark, N.et al. (1998). Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J. Clin. Oncol., 16, 441–52.CrossRefGoogle ScholarPubMed
Fisher, B., Dignam, J., Wolmark, N.et al. (1999). Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet, 353, 1993–2000.CrossRefGoogle ScholarPubMed
Fisher, B., Anderson, S., Tan-Chui, E.et al. (2001). Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J. Clin. Oncol., 19, 931–42.CrossRefGoogle ScholarPubMed
Fisher, B., Anderson, S., Bryant, J.et al. (2002a). Twenty-year follow up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N. Engl. J. Med., 347, 1233–41.CrossRefGoogle Scholar
Fisher, B., Bryant, J., Dignam, J. J.et al. (2002b). Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J. Clin. Oncol., 20, 4141–9.CrossRefGoogle Scholar
Fisher, E. R., Leeming, R., Anderson, S.et al. (1991). Conservative management of intraductal carcinoma (ductal carcinoma in situ) of the breast. Collaborating National Surgical Adjuvant Breast and Bowel Project investigators. J. Surg. Oncol., 47, 139–47.CrossRefGoogle Scholar
Forrest, A. P., Stewart, H. J., Everington, D.et al. (1996). Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Lancet, 348, 708–13.CrossRefGoogle ScholarPubMed
French Adjuvant Study Group. (2001). Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol., 19, 602–11.CrossRef
Fyles, A. W., McCready, D. R., Manchul, L. A.et al. (2004). Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N. Engl. J. Med., 351, 963–70.CrossRefGoogle ScholarPubMed
Goldhirsch, A., Glick, J. H., Gelber, R. D.et al. (2005). Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol., 16, 1569–83.CrossRefGoogle ScholarPubMed
Goss, P. E., Ingle, J. N., Martino, S.et al. (2005). Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Nat. Cancer Inst., 97, 1262–71.CrossRefGoogle ScholarPubMed
Hanrahan, E. O., Hennessy, B. T. and Valero, V. (2005). Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin. Pharmacother., 6, 1477–91.CrossRefGoogle ScholarPubMed
Harris, E. E., Christensen, V. J., Hwang, W. T.et al. (2005). Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J. Clin. Oncol., 23, 11–16.CrossRefGoogle ScholarPubMed
Henderson, I. C., Berry, D. A., Demetri, G. D.et al. (2003). Improved outcomes from adding sequential paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol., 21, 976–83.CrossRefGoogle ScholarPubMed
Holmberg, L., Anderson, H. and HABITS Steering and Data Monitoring Committees. (2004). HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet, 363, 453–5.CrossRefGoogle ScholarPubMed
Howell, A., Cuzick, J., Baum, M.et al. (2005a). Results of the Arimidex, Tamoxifen, Alone or in Combination (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365, 60–2.Google Scholar
Howell, A., Pippen, J., Elledge, R. M.et al. (2005b). Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer, 104, 236–9.CrossRefGoogle Scholar
Huang, J., Barbera, M., Brouwers, M.et al. (2003). Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J. Clin. Oncol., 21, 555–63.CrossRefGoogle ScholarPubMed
Hughes, K. S., Schnaper, L. A., Berry, D.et al. (2004). Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N. Engl. J. Med., 351, 971–7.CrossRefGoogle ScholarPubMed
Jakesz, R., Jonat, W., Gnant, M.et al. (2005). Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of Austrian Breast and Colorectal Cancer Study Group trial 8 and arimidex-nolvadex 95 trial. Lancet, 366, 455–62.CrossRefGoogle Scholar
Joensuu, H., Kellokumpu-Lehtinen, P. L., Bono, P.et al. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med., 354, 809–20.CrossRefGoogle ScholarPubMed
Jonat, W., Gnant, M., Boccardo, F.et al. (2006). Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol., 7, 991–6.CrossRefGoogle ScholarPubMed
Kissin, M. W., Rovere, Querci della G., Easton, D.et al. (1986). Risk of lymphoedema following the treatment of breast cancer. Br. J. Surg., 73, 580–4.CrossRefGoogle ScholarPubMed
Le, M. G., Arriagada, R., Vathaire, F.et al. (1990). Can internal mammary chain treatment decrease the risk of death for patients with medial breast cancers and positive axillary lymph nodes?Cancer, 66, 2313–18.3.0.CO;2-M>CrossRefGoogle ScholarPubMed
Leonard, R. C. and Howell, A. (2000). A systematic review of docetaxel, paclitaxel, and vinorelbine in the treatment of advanced breast cancer. Adv. Breast Cancer, 2, 1–3.Google Scholar
Levine, M. N., Bramwell, V. H., Pritchard, K. I.et al. (1998). Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J. Clin. Oncol., 16, 2651–8.CrossRefGoogle ScholarPubMed
Mamounas, E. P., Bryant, J., Lembersky, B. C.et al. (2003). Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from National Surgical Adjuvant Breast and Bowel Project B-28. Proc. Am. Soc. Clin. Oncol., 22 (4), Abstr. 12.Google Scholar
Mansel, R. E., Fallowfield, L., Goyal, A. et al. (unpublished data). Sentinel node biopsy versus standard axillary treatment in breast cancer: results of the randomized multicentre Axillary Lymphatic Mapping Against Nodal Axillary Clearance trial.
Martin, M., Pienkowski, T., Mackey, J.et al. (2005). Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med., 352, 2302–13.CrossRefGoogle ScholarPubMed
Marty, M., Cognetti, F., Maraninchi, D.et al. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: the M77001 Study Group. J. Clin. Oncol., 23, 4265–74.CrossRefGoogle ScholarPubMed
Mauri, D., Pavlidis, N., Polyzos, N. P.et al. (2006). Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: a meta-analysis. J. Natl. Cancer Inst., 98, 1285–91.CrossRefGoogle Scholar
Miller, K. D., Wang, M., Gralow, J.et al. (2005). A randomized phase III trial of paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005, Abstr. 3.Google Scholar
Miller, W. R., Ellis, I. O., Sainsbury, J. R. C.et al. (1994). ABC of breast diseases. Prognostic factors. B. M. J., 309, 1573–6.CrossRefGoogle ScholarPubMed
Morris, A. D., Morris, R. D., Wilson, J. F.et al. (1997). Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J. Sci. Am., 3, 6–12.Google ScholarPubMed
National Institute for Health and Clinical Excellence. (2002). Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast Cancer. Technology Appraisal Guidance 34. London: National Institute for Health and Clinical Excellence.
National Institute for Health and Clinical Excellence. (2006a). Docetaxel for the Adjuvant Treatment of Early Node-Positive Breast Cancer. Part review of National Institute for Health and Clinical Excellence Technology Appraisal Guidance 30. National Institute for Health and Clinical Excellence Technology Appraisal Guidance 109. London: National Institute for Health and Clinical Excellence.
National Institute for Health and Clinical Excellence. (2006b). Trastuzumab for the Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer. National Institute for Health and Clinical Excellence Technology Appraisal Guidance 107. London: National Institute for Health and Clinical Excellence.
National Institute for Health and Clinical Excellence. (2006c). Familial Breast Cancer. National Institute for Health and Clinical Excellence Clinical Guideline. www.nice.org.uk/guidance/cg41. London: National Institute for Health and Clinical Excellence.
National Institute for Health and Clinical Excellence. (2006d). Hormonal Therapies for the Adjuvant Treatment of Early Oestrogen-Receptor-Positive Breast Cancer. London: National Institute for Health and Clinical Excellence.
National Institutes of Health Consensus Conference. (1991). Treatment of early-stage breast cancer. J. A. M. A., 265, 391–5.CrossRef
Orecchia, R. (2005). Intraoperative radiotherapy to the breast. Breast, 14 (Suppl.), S8.CrossRefGoogle ScholarPubMed
O'Shaughnessy, J., Miles, D., Vukelja, S.et al. (2002). Superior survival with capecitabine plus docetaxel combination chemotherapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J. Clin. Oncol., 20, 2812–23.CrossRefGoogle ScholarPubMed
Overgaard, M., Nielsen, H. M. and Overgaard, J. (2004). Is the benefit of post mastectomy irradiation limited to patients with 4 or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b and c randomized trials. European Society for Therapeutic Radiology and Oncology 2004, Amsterdam, Abstr. 33.Google Scholar
Paik, S., Shak, S., Tang, G.et al. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med., 351, 2817–26.CrossRefGoogle ScholarPubMed
Perez, E. A., Suman, V. J., Davidson, N. et al. (2005). Further analysis of National Central Cancer Treatment Group-N9831. Presented at the American Society of Clinical Oncology Annual Meeting, Orlando, follicular lymphoma (available at www.asco.org.virtualmeeting).
Piccart-Gebhart, M. J. (2005). Herceptin® Adjuvant trial. Presented at the American Society of Clinical Oncology Annual Meeting, Orlando, follicular lymphoma (available at www.asco.org.virtualmeeting).
Poole, C. J., Earl, H. M., Dunn, J. A.et al. (2003). National Epirubicin Adjuvant Trial and Scottish Cancer Trials Breast Group BR9601 phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proc. American Society of Clinical Oncology, Abstr. 13.Google Scholar
Pritchard, K. (2005). Adjuvant endocrine therapies for pre/perimenopausal women. Breast, 14 (Suppl.), S9.CrossRefGoogle ScholarPubMed
Ragaz, J., Olivotto, I. A., Spinelli, J. J.et al. (2005). Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trialJ. Natl. Cancer Inst., 97, 116–26.CrossRefGoogle ScholarPubMed
Royal College of Radiologists. (2006). Recommendations for Cross-Sectional Imaging in Cancer Management. London: Royal College of Radiologists.
Roche, H., Fumoleau, P., Spielmann, M.et al. (2004). Five years analysis of the PACS 01 trial: 6 cycles of 5-FU, epirubicin, cyclophosphamide100 vs 3 cycles of 5-FU, epirubicin, cyclophosphamide100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res. Treat., 89, S16.Google Scholar
Romond, E., Perez, E. A., Bryant, J. et al. (2005). Joint analysis of NSAPB-B-31 and National Central Cancer Treatment Group-N9831. Presented at the American Society of Clinical Oncology Annual Meeting, Orlando, follicular lymphoma (available at www.asco.org.virtualmeeting).
Scottish Intercollegiate Guidelines Network. (2005). Management of Breast Cancer in Women. A National Clinical Guideline. No. 84. Edinburgh: Scottish Intercollegiate Guidelines Network.
Silverstein, M. J. (2003). The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am. J. Surg., 186, 337–43.CrossRefGoogle ScholarPubMed
Slamon, D., Eiermann, W., Robert, N. et al. (2005). Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (Adrenocorticotrophic hormone) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study, presented at San Antonio Breast Cancer Symposium, 2005, Abstr. 1.
Slamon, D. J., Leyland-Jones, B., Shak, S.et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N. Engl. J. Med., 344, 783–92.CrossRefGoogle Scholar
Sorlie, T., Tibshirani, R., Parker, J.et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. United States of America, 100, 8418–23.CrossRefGoogle ScholarPubMed
Thomson, C. S., Brewster, D. H., Dewar, J. A.et al. (2004). Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment. Eur. J. Cancer, 40, 743–53.CrossRefGoogle ScholarPubMed
Thurlimann, B., Keshaviah, A., Coates, A. S.et al. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med., 353, 2747–57.Google ScholarPubMed
International Union Against Cancer. (2002). tumour nodes metastases Classification of Malignant Tumours, 6th edn., ed. Sobin, L. H. and Ch. Wittekind, . New York: Wiley-Liss, pp. 131–41.Google Scholar
Veronesi, U., Cascinelli, N., Mariani, L.et al. (2002). Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med., 347, 1227–32.CrossRefGoogle ScholarPubMed
Veronesi, U., Paganelli, G., Viale, G.et al. (2003). A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med., 349, 546–53.CrossRefGoogle ScholarPubMed
Wallner, P., Arthur, D., Bartelink, H.et al. (2004). Workshop on partial breast irradiation: state of the art and the science. J. Natl. Cancer Inst., 96, 175–84.CrossRefGoogle Scholar
Wolmark, N., Dignam, J., Margolese, R.et al. (2000). The role of radiotherapy and tamoxifen in the management of node-negative breast cancer -1.0 cm treated with lumpectomy: preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol B-21. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 19, A271. Abstr.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Breast
    • By Nayyer Iqbal, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, Peter Barrett-Lee, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.017
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Breast
    • By Nayyer Iqbal, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, Peter Barrett-Lee, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.017
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Breast
    • By Nayyer Iqbal, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, Peter Barrett-Lee, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.017
Available formats
×